Achieving Intensive Blood Pressure Control in High-Risk Patients: Implementation Insights From the ESPRIT Trial.

This study examined whether doctors could help high-risk heart patients achieve very tight blood pressure control (systolic pressure below 120 mm Hg) in real-world settings. Researchers followed 11,255 patients (average age 65, 41% women) who had high cardiovascular risk, including many with long-term uncontrolled blood pressure. They compared intensive blood pressure targets (below 120) to standard targets (below 140).

The study found that 62.5% of patients in the intensive treatment group successfully reached the lower blood pressure goal, with a median blood pressure of 117 mm Hg. Most patients achieved this control within about two months. However, older patients, men, those with diabetes, stroke history, or longer hypertension duration found it harder to reach these targets. Achieving intensive control required an average of 3.3 blood pressure medications compared to 2.0 for standard treatment, and patients needed about 6.9 clinic visits in the first year versus 5.4 for standard care.

Importantly, the intensive approach reduced major cardiovascular events and death without significant safety concerns across diverse patient groups, including those with longstanding uncontrolled blood pressure. The study demonstrates that very tight blood pressure control is achievable with modest additional medical resources.

For patients considering acupuncture, this research focuses on pharmaceutical blood pressure management rather than complementary therapies. While acupuncture may support cardiovascular health as part of an integrative approach, this study does not address acupuncture's role. If you're interested in acupuncture for blood pressure support, consult a licensed acupuncturist certified by the National Certification Commission for Acupuncture and Oriental Medicine (NCCAOM).

The ESPRIT trial analyzed implementation of intensive systolic blood pressure control (<120 mm Hg) in 11,255 high-risk hypertensive patients (mean age 64.6±7.1 years, 41.3% female). Results showed 62.5% achieved intensive control with median SBP of 117 mm Hg (IQR: 113-123). Median time to intensive control was 62 days (IQR: 33-96). Patients with advanced age, male sex, higher baseline SBP, diabetes, stroke history, or hypertension duration ≥10 years were less likely to achieve sustained control. Intensive treatment required mean 3.3 medications versus 2.0 for standard care, and 6.9 versus 5.4 first-year clinic visits. No significant treatment interaction existed across subgroups except myocardial infarction (P=0.019). The trial demonstrates intensive BP targets are achievable in diverse populations with modest additional resources, with consistent cardiovascular benefits regardless of baseline control status or hypertension duration. This study provides no data on acupuncture interventions for hypertension management.